As more Americans wrestle with the cost of their health care, they continue to gravitate toward better lifestyle choices, which means niche products that were at one time only purchased by body builders and serious athletes have become appealing to the mainstream consumer.
One of the biggest trends in food and beverage in the past several years has been in better-for-you offerings — something that’s expected to continue to influence new products as consumers remain focused on what’s in their favorite snacks and beverages.
There is no question that one of the top nonprescription categories contributing to both sales and foot traffic right now is allergy. Sales of nasal sprays — the category that captures all of the latest nasal corticosteroid Rx-to-OTC switches — are up 10.2%.
This could be the year. Movement again is occurring in Congress on legislation that would confer professional provider status on pharmacists serving millions of older Americans in many parts of the country.
Legislation pending in both houses of Congress regarding DIR, or direct and indirect remuneration, fees are giving hope to drug stores and two of the industry’s largest advocacy groups that pharmacy benefits management companies will stop retroactively reducing payments.
Although 2016 saw the Food and Drug Administration approve only 22 new drugs compared with 45 approvals in 2015 and the lowest tally since 2010, many in the pharmaceutical arena remain optimistic that this year will see a reversal of that trend.